Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01131104

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

Nonarteritic Anterior Ischemic Optic Neuropathy Clinical Trial

Official title:
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Clinical Trial Summary

Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION) in males. Subjects with newly diagnosed NAION will be asked via a structured questionnaire about their use of PDE5 inhibitors and other risk factors prior to the onset of their vision loss.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01131104
Study type Observational
Source Eli Lilly and Company
Contact
Status Completed
Phase
Start date May 2010
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT00561834 - Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy Phase 1
Completed NCT00432393 - Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Phase 4
Terminated NCT03547206 - Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Phase 2